help me understand pentadecapeptide, I have read the wiki twice
Trying to get a straight answer on this: help me understand pentadecapeptide, I have read the wiki twice.
Asked SGN for the theoretical mass alongside the certificate and they sent it without asking why.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
Why identity, not purity, is the test to buy here.
This is a short peptide with a published sequence. Synthesis is not difficult, which means the market is wide and the analytical question shifts. A high area-percent figure tells you the sample is homogeneous; it does not tell you the homogeneous material is the sequence you ordered.
Mass spectrometry, with the theoretical mass alongside the measured one, converts a purity claim into an identity claim. It costs a little more and it answers the question that actually matters. Ask for it, and ask suppliers whether they can provide it before you order — the answers are informative in themselves.
Tell me where this is wrong. That is the useful part of posting it.
best — the order this archive was captured in
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
Right, and regulatory status has genuinely moved in several jurisdictions. Answers from three years ago may be wrong now.
Citation requested rather than removal. A claim here should say whether its source is preclinical.
Has anyone posted an independent result on that batch?
Do you have the mass spectrum?
What jurisdiction are you asking about? The answer has changed in several.
no clinical trial has established what these threads assert
research-use-only means not approved for human use, and here that covers everything
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
What method produced that purity number?
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
preclinical enthusiasm is not clinical evidence
Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.
identity testing matters more here than purity does
The three questions, kept separate, because this board runs them together constantly.
Identity: is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity: how much peptide is in the vial? Answered by net peptide content, not by area percent. Stability: what happens to it in solution over time? Answered by a stability statement with conditions attached, and almost never asked for.
A certificate that answers one of the three is common. One that answers all three is rare and worth choosing a supplier over. Nothing here is approved for human use in any case, so all three are questions about material rather than about anything else.
pentadecapeptide, fifteen residues, and the sequence is public
The three questions, kept separate, because this board runs them together constantly.
This is the point that should be at the top of every thread here. Identity first.
Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.
Assumed regulatory status was static and it was not.
hplc_hobbyist is right that a pure something-else is still something else.
Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.
Reconstituted or powder, and how long has it been in solution?
Not convinced.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
The evidence base, described honestly, which almost no summary of it does.
The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.
That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.
I would not extrapolate a mechanism from a model system to a person in one step, which is what that comment does.
- 1What jurisdiction are you asking about? The answer has changed in several.6 comments in this branch · started by u/ruben_cabrera